Dr. Linda T. Van Le, MD

Dr. Van Le practices at UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System.

Dr. Van Le's NPI, 1073601365, was assigned on October 11, 2006. Dr. Van Le graduated from University of California, San Francisco School of Medicine in 1983. Dr. Van Le holds North Carolina license 38230.

Dr. Van Le's primary practice is UNC Hospitals, at 101 Manning Drive, Chapel Hill, NC 27514 in Orange County. The practice phone is (919) 966-4141.

Dr. Van Le's primary practice is UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System. The medical group on file is UNC Faculty Physicians. Dmand AI also links Dr. Van Le to 1 more therapy and rehab clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Van Le practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Van Le's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Van Le is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dr. Van Le is licensed in North Carolina.

CMS data shows 47 Medicare services from Dr. Van Le across 1 procedure code in 2024, all of them office visits, for 50 Medicare patients. Medicare paid $1,837 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 50 Medicare patients who saw Dr. Van Le in 2024. The largest group is 65 to 74, with 29 patients. 75% of them have high blood pressure, and 62% have high cholesterol. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Van Le's median patient age at 73, with 100% women.

In 2024, Dr. Van Le wrote 54 Medicare Part D claims for 19 patients. 81% of them were for generic drugs. CMS names the drug for 42 of them, across 3 drugs with 11 or more claims each, at $1,070 in total drug cost. In 2022, CMS named 53 claims across 3 drugs.

Dr. Van Le accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 41 papers to Dr. Van Le, published from 2011 to 2024. 2015 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial and Endometrial Neoplasms. Dr. Van Le has published most often in Gynecol Oncol. Dr. Van Le's most frequent co-authors are Paul Andrew Disilvestro, MD, Krishnansu Sujata Tewari, MD and Emily M. Ko, MD.

Dmand AI links Dr. Van Le to 10 clinical trials, 5 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Uterine Cervical Neoplasms, Uterine Cervical Diseases and Fallopian Tube Diseases. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 3 general payments to Dr. Van Le from 2 drug and device companies from 2023 to 2024. Consulting fees make up the largest share, 84% of the total. GlaxoSmithKline, LLC. paid the most, $515.

Dr. Van Le graduated from University of California, San Francisco School of Medicine in 1983.